Murdoch University, Perth, WA, Australia.
Cell Mol Immunol. 2011 May;8(3):213-25. doi: 10.1038/cmi.2010.77. Epub 2011 Jan 31.
Microbes are increasingly being implicated in autoimmune disease. This calls for a re-evaluation of how these chronic inflammatory illnesses are routinely treated. The standard of care for autoimmune disease remains the use of medications that slow the immune response, while treatments aimed at eradicating microbes seek the exact opposite-stimulation of the innate immune response. Immunostimulation is complicated by a cascade of sequelae, including exacerbated inflammation, which occurs in response to microbial death. Over the past 8 years, we have collaborated with American and international clinical professionals to research a model-based treatment for inflammatory disease. This intervention, designed to stimulate the innate immune response, has required a reevaluation of disease progression and amelioration. Paramount is the inherent conflict between palliation and microbicidal efficacy. Increased microbicidal activity was experienced as immunopathology-a temporary worsening of symptoms. Further studies are needed, but they will require careful planning to manage this immunopathology.
微生物越来越多地与自身免疫性疾病有关。这要求我们重新评估这些慢性炎症性疾病的常规治疗方法。自身免疫性疾病的标准治疗方法仍然是使用减缓免疫反应的药物，而旨在消除微生物的治疗方法则寻求完全相反的效果——刺激先天免疫反应。免疫刺激受到一系列后果的影响，包括加剧的炎症，这是对微生物死亡的反应。在过去的 8 年中，我们与美国和国际临床专业人员合作，研究一种基于模型的炎症性疾病治疗方法。这种干预措施旨在刺激先天免疫反应，这需要重新评估疾病的进展和改善。至关重要的是缓解和杀菌效果之间固有的冲突。杀菌活性的增加被认为是免疫病理学——症状的暂时恶化。需要进一步的研究，但需要仔细规划来管理这种免疫病理学。
